Among the 8890 patients in a propensity score-matched cohort all with hormone receptor-positive, node-negative BC and a high RS of >25, we identified a significant benefit from chemotherapy (HR = 0.782; 95% CI, 0.618–0.990, p = 0.041); this finding reconfirmed the evidence that adjuvant chemotherapy was beneficial in this group of patients [3,12,13]. This evidence concerns the gene NR4A1 and breast cancer.